258 related articles for article (PubMed ID: 21741831)
1. The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses.
Campbell HE; Epstein D; Bloomfield D; Griffin S; Manca A; Yarnold J; Bliss J; Johnson L; Earl H; Poole C; Hiller L; Dunn J; Hopwood P; Barrett-Lee P; Ellis P; Cameron D; Harris AL; Gray AM; Sculpher MJ
Eur J Cancer; 2011 Nov; 47(17):2517-30. PubMed ID: 21741831
[TBL] [Abstract][Full Text] [Related]
2. Information technology facilitates cost-effectiveness analysis in developing countries: an observational study of breast cancer chemotherapy in Taiwan.
Shih YC; Pan IW; Tsai YW
Pharmacoeconomics; 2009; 27(11):947-61. PubMed ID: 19888794
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant fluorouracil, epirubicin and cyclophosphamide in early breast cancer: is it cost-effective?
Norum J; Holtmon M
Acta Oncol; 2005; 44(7):735-41. PubMed ID: 16227165
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal.
Chilcott J; Lloyd Jones M; Wilkinson A
Health Technol Assess; 2009 Jun; 13 Suppl 1():7-13. PubMed ID: 19567208
[TBL] [Abstract][Full Text] [Related]
6. Cost analysis comparing an anthracycline/docetaxel regimen to CMF in patients with early stage breast cancer.
Braun M; Jacobs VR; Wagenpfeil S; Sattler D; Harbeck N; Nitz U; Bernard R; Kuhn W; Ihbe-Heffinger A
Onkologie; 2009 Sep; 32(8-9):473-81. PubMed ID: 19736510
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis.
Wolowacz SE; Cameron DA; Tate HC; Bagust A
J Clin Oncol; 2008 Feb; 26(6):925-33. PubMed ID: 18281666
[TBL] [Abstract][Full Text] [Related]
8. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial.
Ellis P; Barrett-Lee P; Johnson L; Cameron D; Wardley A; O'Reilly S; Verrill M; Smith I; Yarnold J; Coleman R; Earl H; Canney P; Twelves C; Poole C; Bloomfield D; Hopwood P; Johnston S; Dowsett M; Bartlett JM; Ellis I; Peckitt C; Hall E; Bliss JM; ;
Lancet; 2009 May; 373(9676):1681-92. PubMed ID: 19447249
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy in early breast cancer.
Ejlertsen B
Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100.
Younis T; Rayson D; Sellon M; Skedgel C
Breast Cancer Res Treat; 2008 Sep; 111(2):261-7. PubMed ID: 17914669
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D.
Lee EK; Wong WW; Trudeau ME; Chan KK
Breast Cancer Res Treat; 2015 Feb; 150(1):169-80. PubMed ID: 25694355
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF) in breast cancer--is it cost-effective?
Norum J
Acta Oncol; 2000; 39(1):33-9. PubMed ID: 10752651
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects.
Au HJ; Golmohammadi K; Younis T; Verma S; Chia S; Fassbender K; Jacobs P
Breast Cancer Res Treat; 2009 Apr; 114(3):579-87. PubMed ID: 18443903
[TBL] [Abstract][Full Text] [Related]
14. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
Crump M; Tu D; Shepherd L; Levine M; Bramwell V; Pritchard K
J Clin Oncol; 2003 Aug; 21(16):3066-71. PubMed ID: 12915595
[TBL] [Abstract][Full Text] [Related]
15. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
[TBL] [Abstract][Full Text] [Related]
16. An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK.
Benedict A; Cameron DA; Corson H; Jones SE
Pharmacoeconomics; 2009; 27(10):847-59. PubMed ID: 19803539
[TBL] [Abstract][Full Text] [Related]
17. Selection of adjuvant chemotherapy for treatment of node-positive breast cancer.
Trudeau M; Charbonneau F; Gelmon K; Laing K; Latreille J; Mackey J; McLeod D; Pritchard K; Provencher L; Verma S
Lancet Oncol; 2005 Nov; 6(11):886-98. PubMed ID: 16257797
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of docetaxel versus weekly paclitaxel in adjuvant treatment of regional breast cancer in New Zealand.
Webber-Foster R; Kvizhinadze G; Rivalland G; Blakely T
Pharmacoeconomics; 2014 Jul; 32(7):707-24. PubMed ID: 24859241
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: doxorubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide.
Liubao P; Xiaomin W; Chongqing T; Karnon J; Gannong C; Jianhe L; Wei C; Xia L; Junhua C
Pharmacoeconomics; 2009; 27(10):873-86. PubMed ID: 19803541
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of docetaxel (Taxotere) vs. 5-fluorouracil in combined therapy in the initial phases of breast cancer.
Martín-Jiménez M; Rodríguez-Lescure A; Ruiz-Borrego M; Seguí-Palmer MA; Brosa-Riestra M
Clin Transl Oncol; 2009 Jan; 11(1):41-7. PubMed ID: 19155203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
